Kura Oncology (NASDAQ:KURA) Reaches New 1-Year Low – Here’s Why

Kura Oncology, Inc. (NASDAQ:KURA)’s stock price reached a new 52-week low on Monday . The stock traded as low as $8.47 and last traded at $8.51, with a volume of 208537 shares changing hands. The stock had previously closed at $8.67.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on KURA. Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and cut their price objective for the stock from $26.00 to $19.00 in a report on Monday, October 14th. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. JMP Securities reiterated a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a research report on Tuesday, November 19th. Finally, HC Wainwright lifted their price target on Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.86.

Kura Oncology Stock Down 2.9 %

The stock has a market capitalization of $654.77 million, a P/E ratio of -3.57 and a beta of 0.75. The stock has a 50 day moving average price of $13.36 and a 200-day moving average price of $17.67. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Hedge Funds Weigh In On Kura Oncology

A number of large investors have recently bought and sold shares of KURA. Sofinnova Investments Inc. boosted its stake in shares of Kura Oncology by 64.4% during the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after purchasing an additional 323,303 shares during the period. Armistice Capital LLC boosted its position in Kura Oncology by 14.7% during the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after buying an additional 302,000 shares during the period. Candriam S.C.A. grew its holdings in Kura Oncology by 39.2% in the 2nd quarter. Candriam S.C.A. now owns 906,482 shares of the company’s stock worth $18,664,000 after acquiring an additional 255,065 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Kura Oncology by 34.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,060 shares of the company’s stock valued at $372,000 after acquiring an additional 4,654 shares during the period. Finally, HighVista Strategies LLC bought a new position in shares of Kura Oncology during the second quarter valued at about $345,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.